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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a form of chronic fibrosing interstitial pneumonia characterized
by progressive worsening of dyspnea and lung function, with a poor prognosis. The objective of this study was to
determine treatment patterns, resource use and costs of managing Spanish patients with IPF.
Methods: A three-round Delphi consensus panel of 15 clinical experts was held between December 2012 and June
2013 using questionnaires to describe the management of patients with IPF. A cost analysis based on Delphi panel
estimates was made from the Spanish National Health System (NHS) perspective, including the direct costs of IPF
diagnosis and management. Unit costs were applied to Delphi panel estimates of health resource use. Univariate
sensitivity analyses were made to evaluate uncertainties in parameters.
Results: The Delphi panel estimated that 20, 60 and 20 % of IPF patients presented with stable disease, slow and
rapid disease progression, respectively. The estimated annual cost per patient with stable disease, slow and rapid
disease progression was €11,484, €20,978 and €57,759, respectively. This corresponds to a weighted average annual
cost of €26,435 with itemized costs of €1,184 (4.5), €7,147 (27.0), €5,950 (22.5), €11,666 (44.1) and €488 (1.9 %) for the
diagnosis of IPF, treatment, monitoring, management of acute exacerbations and end-of-life care, respectively. The
parameter that varied the annual cost per patient the most was resource use associated with acute exacerbations.
Conclusions: The management of patients with IPF in Spain, especially patients with rapid disease progression, has a
high economic impact on the NHS.
Keywords: Costs, Delphi technique, Idiopathic pulmonary fibrosis, Spain
Background
Idiopathic pulmonary fibrosis (IPF) is a specific form of
chronic, progressive fibrosing interstitial pneumonia
associated with the histopathological and/or radiological
pattern of usual interstitial pneumonia (UIP) [1]. A diag-
nosis of IPF requires the exclusion of other forms of
interstitial lung disease (ILD) such as those associated
with environmental exposure, medication or systemic
disease [1]. IPF usually affects adults aged >50 years; the
prevalence is higher in males and most patients have a
history of smoking [1–3].
IPF is characterised by progressive worsening of dys-
pnoea and lung function, with a poor prognosis, but the
natural history of the disease is variable and unpredictable
in the individual patient [1]. In most patients, IPF worsens
slowly but steadily (“slow progression”), in some it
remains stable (“stable”) and in some it worsens rapidly
(“rapid progression”) [1]. In addition, some patients
experience acute exacerbations, defined as episodes of
acute respiratory worsening of unknown cause [4].
In the past, IPF was considered to have an inflammatory
origin and, consequently, anti-inflammatory and immuno-
suppressive drugs have been used [5, 6]. However, the
central event currently considered to be involved in the
development of IPF is repeated alveolar epithelial cell
injury resulting in an impaired repair process with devel-
opment of fibrosis with inflammation now considered less
important [7]. This scenario has encouraged the develop-
ment of new drugs with antifibrotic properties [8].
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The overall economic burden associated with IPF in
Spain remains unknown. Studies analysing the cost of
illness could help to define the magnitude of economic
burden associated with IPF and its impact on Spanish
society. The objective of this study, which used a Delphi
panel, was to determine treatment patterns, resource use
and the associated costs of managing patients with IPF
in the Spanish healthcare system.
Methods
Delphi panel
A three-round Delphi panel of clinical experts was held
between December 2012 and June 2013 using postal ques-
tionnaires to describe the treatment patterns and resource
use associated with IPF. The first questionnaire included
questions on the clinical management of patients with IPF
in Spain and open questions that investigated several
aspects of the disease. The second questionnaire sought to
study specific issues in greater detail and to resolve any
doubts about questions asked in the first questionnaire.
The third questionnaire was carried out to reach a
consensus among the experts. An aggregate of the
three questionnaires is available on the journal website
(Additional file 1). In each round, the participants were
asked the questions individually. All participants remained
anonymous until the end of the process.
Fifteen pulmonologists who were experts on ILD were
recruited from the Spanish respiratory community to en-
sure that the findings of the Delphi panel were credible and
reflective of clinical practice in Spain. Pulmonologists were
recruited from different Spanish Autonomous Communi-
ties to guarantee that regional differences were captured
(Andalusia, Asturias, Castile-La Mancha, Castile-Leon,
Catalonia, Community of Madrid, Valencian Community,
Galicia) (see Acknowledgements). The study sponsor did
not influence selection of the panelists and was unaware of
their identity until study completion. Study panelists were
unaware of the identity of the study sponsor. The study did
not require approval from an ethics committee due to its
design [9].
Cost analysis
A cost analysis was made from the Spanish National Health
System (NHS) perspective, based on data obtained through
a systematic literature review and the Delphi panel esti-
mates of the number of patients with IPF in Spain and their
resource use during diagnosis, treatment (pharmacological
and non-pharmacological) and management (medical visits,
tests, other resources). All costs were estimated per patient
per year, and were specified with respect to the different
types of disease course. To calculate an overall annual cost
per patient, the estimated cost associated with each type of
disease course was weighted by its proportion of all pa-
tients. Costs were expressed in 2013 euro.
Unit costs
Unit costs were obtained from Spanish databases (see
Additional file 2: Table S1, Table 1). Pharmacological costs
were obtained from the Spanish database of the Consejo
General de Colegios Oficiales de Farmacéuticos, and all
costs included were ex-factory price [10]. Unit costs re-
lated to medical visits, tests, hospital admissions, etc. were
obtained from the eSalud Spanish health costs database
[11]. Diagnostic-related group costs were obtained from
the Spanish Ministry of Health database [12].
Types of disease course in IPF
The expert panel estimated the proportion of patients
with IPF with stable disease, slow and rapid disease
progression, according to the types of disease courses
described in the ATS/ERS/JRS/ALAT Statement [1].
Treatment and monitoring costs were estimated accord-
ing to the type of disease course. The costs associated
with an acute exacerbation were assumed to be the same
for all types of patients. The annual cost for each type of
disease course was calculated by weighting the cost
according to the number of exacerbations per each type
of patient per year. A similar approach was used to esti-
mate costs associated with end-of-life care. The cost per
year associated with end-of-life care was weighted by the
survival rates observed per type of disease course.
Epidemiological approach
The cost of illness analysis was performed using a
prevalence-based approach, as this method allows disease-
Table 1 Cost of management of adverse events associated with
the treatment of IPF
Non-hospitalised grade
3 adverse eventsa





Cushing syndrome €74.66 €4,468.42
Compression fractures €74.66 €3,495.47
Diabetes €84.74 €3,898.39





Nausea €68.14 € 3,082.73
Digestive intolerance €74.66 b
Nasal dryness €27.95 €1,678.20
Asthenia b €3,082.73
Source: eSalud [11]
aCosts were estimated taking into account medical visits and tests undergone
by patients for their management
bThese adverse events were reported by <5 % of patients therefore these
costs were not included
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attributable costs that occur concurrently with prevalent
cases over a specified time period (1 year in this case) to
be measured [13]. To calculate the current number of pa-
tients with IPF in Spain, the median prevalence obtained
through the Delphi panel was multiplied by the Spanish
population obtained from the Spanish National Statistics
Institute [14].
Diagnostic costs
To calculate the number of patients diagnosed with IPF,
the diagnostic rate was assumed to be 85 %, based on a
series of patients with clinical characteristics of ILD [15],
This rate was applied to the number of Spanish patients
estimated by the Delphi panel. To estimate the total cost
associated with the diagnosis of IPF, the median number
of medical visits or tests carried out to reach the diagno-
sis was multiplied by their mean unit costs. To deter-
mine the cost of diagnosis per year, the estimated total
cost associated with the diagnosis of IPF was multiplied
by the ratio of incidence over prevalence.
Treatment of patients with IPF by disease course
The cost associated with pharmacological therapies in-
cluded drugs and the cost of drug-related adverse events.
The mean cost per unit and the daily median dose admin-
istered were multiplied by the median treatment duration.
Only drug-related adverse events affecting >5 % of
patients were included and costs associated with Common
Terminology Criteria for Adverse Events grade 1–2 (mild
and moderate) adverse events were excluded [16]. The
cost associated with grade 3 (severe) adverse events
included the cost of patients hospitalised due to adverse
events and resource use by non-hospitalised patients
(Table 1). It was assumed that all patients suffering
grade 4 (potentially life threatening) adverse events
were hospitalised. To calculate the costs associated
with non-pharmacological therapies, the percentages
of patients undergoing lung transplantation or pul-
monary rehabilitation were multiplied by their unit
costs (see Additional file 2: Table S1).
Monitoring by clinical disease course per year
To estimate the cost associated with IPF monitoring, the
mean unit costs of medical visits, tests and hospital admis-
sions (see Additional file 2: Table S1) were multiplied by
the median number of resources used per type of patient
and year according to estimates from the Delphi panel.
Management of patients during acute exacerbations
The total number of acute exacerbations suffered per
type of patient/year was calculated to estimate the costs
associated with their management per year according to
the estimates of the Delphi panel. Diagnosis, treatment,
healthcare resource use and follow-up costs were
included. To calculate the cost associated with diagnosis,
unit costs related to tests carried out to differentiate
acute exacerbations from other causes of acute respira-
tory failure or clinical deterioration were multiplied by
the percentage of patients undergoing each test as esti-
mated by the Delphi panel. Treatment costs associated
with acute exacerbations were included. To calculate the
costs associated with each therapeutic regimen, the
mean cost per unit and the daily median dose were
multiplied by the duration of treatment. The associated
costs of healthcare resource use and follow-up during an
acute exacerbation were estimated, and the unit costs of
medical visits and tests were multiplied by the percent-
age of patients receiving them. To estimate the overall
cost per year associated with acute exacerbations for
each type of disease course, the total cost of an acute ex-
acerbation was multiplied by the number of acute exac-
erbations suffered per year by each type of patient.
End-of-life care
Treatment costs were calculated by multiplying mean
unit costs, median doses administered and the duration
of each treatment by the percentage of patients receiving
each treatment according to Delphi panel estimates. To
calculate the costs associated with outpatient visits, the
median number of visits per patient was multiplied by
their unit cost. To distribute end-of-life care costs annu-
ally, the annual mortality rate per type of disease course
was multiplied by the total end-of-life cost, in order to
weight this cost by the proportion of patients who re-
ceive end-of-life care per year. The annual mortality rate
was calculated using a DEALE approximation (Declining
Exponential Approximation to Life Expectancy) [17].
Sensitivity analysis
Successive univariate sensitivity analyses were performed
on key values in the cost analysis to ascertain the cir-
cumstances under which uncertainty or lack of agree-
ment about any estimate may significantly impact the
results. Specific parameters were varied one at a time
across a plausible range, while the remaining values were
held at baseline values. The parameters varied were the
prevalence and incidence estimates made by the Delphi
panel (±25 %), resource use associated with the manage-
ment of IPF derived from the Delphi panel (minimum
and maximum values), and unit costs obtained from
Spanish databases (minimum and maximum values).
Results
Delphi panel
The first round Delphi Panel was completed by 15 pul-
monologists and the second and third rounds by 14. The
degree of consensus in the third questionnaire was high,
with 77–100 % agreement per question.
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Epidemiological estimates by the Delphi panel sug-
gested that the prevalence of IPF in Spain is 12 cases per
100,000 people/year and the incidence is 3 cases per
100,000 people/year. Based on a Spanish population of
46,039,979, it was calculated that there are 5,525 people
with IPF in Spain.
Considering a diagnostic rate of 85 % [15], the number
of diagnosed patients with IPF in Spain was estimated to
be 4,696. The Delphi panel estimated that two primary care
visits, three pulmonary medicine department visits, mul-
tiple laboratory tests and other tests such as chest x-ray,
high resolution computed tomography (HRCT), bronchos-
copy, bronchoalveolar lavage, transbronchial biopsy, surgi-
cal lung biopsy, blood gases and respiratory function tests
were carried out to reach a diagnosis of IPF.
It was estimated that 20, 60 and 20 % of IPF patients
presented with stable disease, slow and rapid disease
progression, respectively, and that mean survival after
diagnosis was 66, 42 and 15 months, respectively.
The Delphi panel estimated that most patients with
IPF are administered N-acetylcysteine (Table 2). All pa-
tients with rapid disease progression also receive long-
term oxygen therapy and half are treated with prednis-
one (Table 2). N-acetylcysteine does not induce grade 3–
4 adverse events (Table 3). The main grade 3–4 adverse
events associated with prednisone are osteoporosis, my-
opathy, hyperglycemia, Cushing syndrome and diabetes
(Table 3). The main grade 1–4 adverse event associated
with long-term oxygen therapy is nasal dryness (Table 3).
Some patients are also treated with non-pharmacological
therapies such as pulmonary rehabilitation (10 % of pa-
tients) and single-lung transplant (5 and 8 % of patients
with slow and rapid disease progression, respectively)
(Table 2).
Table 4 shows that patients with rapid disease progres-
sion used the most healthcare resources.
The Delphi panel estimated that the number of exacer-
bations per patient/year was 0.76 in patients with stable
disease, 0.82 in patients with slow disease progression
and 1.8 in patients with rapid progression. The panel
estimated that 51 % of patients with IPF with an acute
exacerbation die from this event. Of these, 69 die in the
hospital and 31 % during the 6 months after hospital dis-
charge. Tests performed in more than 50 % of patients
with IPF to differentiate an acute exacerbation from
other causes of acute respiratory failure or clinical de-
terioration included computed tomography, echocardi-
ography and laboratory tests. Table 4 shows that, during
an acute exacerbation and follow-up, patients use









N-acetylcysteine 80 % 100 % 100 %
Anticoagulants 0 % 0 % 4.3 %
Prednisone 0 % 0 % 50 %
Long-term oxygen therapy 25 % 30 % 100 %
Omeprazole or pantoprazole 7 % 7 % 7 %
Pirfenidone (compassionate
use /importation)
0 % 5 % 0 %
Non-pharmacological
Single-lung transplant 0 % 5 % 8 %
Pulmonary rehabilitation 10 % 10 % 10 %
Table 3 Adverse events associated with IPF treatments
% of patients
Grade 1–2 Grade 3 Grade 4
N-Acetylcysteine
Epigastric pain 5 % 0 % 0 %
Digestive intolerance 8 % 0 % 0 %
Dyspepsia 5 % 0 % 0 %
Reflux 1 % 0 % 0 %
Nausea 1 % 0 % 0 %
Anticoagulants
Haematoma 10 % 0 % 0 %
Systemic corticosteroids
Osteoporosis 30 % 18 % 5 %
Opportunistic infections 10 % 5 % 1 %
Oedema 10 % 3 % 0 %
Myopathy 15 % 5 % 5 %
Hyperglycaemia 30 % 18 % 5 %
Cushing syndrome 20 % 10 % 5 %
Compression fractures 10 % 10 % 3 %
Diabetes 15 % 10 % 5 %
Hypertension 10 % 5 % 0 %
Cataracts 8 % 5 % 1 %
Digestive intolerance 10 % 7 % 3 %
Pirfenidone
Photosensitivity 20 % 0 % 0 %
Epigastric pain 15 % 3 % 0 %
Skin reactions 15 % 0 % 0 %
Nausea 8 % 10 % 0 %
Asthenia 10 % 3 % 0 %
Digestive intolerance 10 % 8 % 0 %
Long-term oxygen therapy
Nasal dryness 40 % 10 % 3 %
Epistaxis 10 % 0 % 0 %
Dry mouth 8 % 3 % 0 %
Morell et al. BMC Pulmonary Medicine  (2016) 16:7 Page 4 of 9
considerable healthcare resources, including medical
visits, hospitalisations and multiple tests. Treatments ad-
ministered to treat acute exacerbations were corticoste-
roids (100 of patients), antibiotics (93), and
anticoagulant drugs (79) and non-invasive (79) and inva-
sive (71 %) mechanical ventilation.
The Delphi panel estimated that, during end-of-life care,
most physicians initiate palliative care when patients with
IPF develop uncontrollable dyspnoea. Annual mortality
rates were 18.2, 28.6 and 80 % in patients with stable dis-
ease, slow and rapid disease progression, respectively. The
median duration of palliative treatment was 4.5 months.
The main active ingredients administered as palliative
treatment were paracetamol (50 of patients), codeine (40),
morphine (40) and corticosteroids (20 %).
Costs
The total cost of the diagnosis of IPF was €4,736 per pa-
tient. When this cost was distributed by the proportion
of new patients diagnosed every year (by multiplying
with the ratio of incidence over prevalence), there was
an annual cost of €1,184 per patient (Table 5). The main
cost drivers were surgical lung biopsy, bronchoscopy
with bronchoalveolar lavage and transbronchial biopsy
and pulmonary medicine department visits.
Table 4 Median healthcare resource use for managing acute exacerbations and follow-up of patients with IPF
Acute exacerbation
and follow-up
Management and follow-up of patients with IPF (over a 3-month period)
Stable disease Slow disease progression Rapid disease progression
Outpatient visits
General practitioner home visits 0.2 0.0 0.0 0.0
Pulmonary specialist 2.0 1.0 1.0 2.0
Nurse (or other healthcare professional) 0.6 0.0 0.0 0.0
Elective ambulance 0.3 0.0 0.0 0.0
Emergency
Emergency room visits 1.0 0.0 0.0 1.0
Emergency ambulance 0.8 0.0 0.0 0.0
Hospital admissions
Pulmonary department (days) 11.3 0.0 0.0 7.5
Intensive care unit (days) 2.5 0.0 0.0 0.8
Laboratory tests
Complete blood count 3.0 1.0 1.0 1.0
Sedimentation rate 2.0 0.0 1.0 1.0
Liver profile 2.0 0.0 1.0 1.0
Creatine phosphokinase 1.5 0.0 0.0 1.0
Urinalysis 0.2 0.0 0.0 0.0
Microbiology 0.1 0.0 0.0 0.0
Respiratory function tests
Spirometry 1.0 1.0 1.0 1.0
Body plethysmography 0.1 0.0 1.0 1.0
Diffusing capacity of carbon monoxide 1.0 0.0 1.0 1.0
6-min walk test 0.3 0.0 1.0 1.0
Other tests
Chest X-ray 3.0 0.0 0.5 1.0
High-resolution computed tomography 1.0 0.0 0.0 1.0
Blood gases 3.0 0.0 0.3 1.5
Computed tomography pulmonary angiogram 0.3 0.0 0.0 0.0
Bronchoscopy 0.3 0.0 0.0 0.0
Sputum assessment 0.8 0.0 0.0 0.0
Bronchoalveolar lavage 0.2 0.0 0.0 0.0
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The mean associated cost of treatment per patient/year
was €722 for patients with stable disease, €8,069 for
patients with slow disease progression and €10,803 for
patients with rapid disease progression (Table 5). The high
cost in patients with slow disease progression and rapid
disease progression was mainly attributable to the cost of
lung transplantation. When total costs per patient were
weighted by the proportion of patients with each type of
disease course, an overall cost of €7,147 was obtained per
patient/year (Table 5).
The annual mean costs associated with IPF monitoring
were €454, €1,699 and €24,199 per patient with stable
disease, slow and rapid disease progression, respectively
(Table 5). The most costly resources were those associ-
ated with pulmonary specialist visits and spirometry
tests for patients with stable disease, diffusing capacity
of carbon monoxide and 6-min walk tests for patients
with slow disease progression, and hospital admissions
for patients with rapid disease progression. The cost
weighted by types of disease course showed an overall
cost of €5,950 per IPF patient/year (Table 5).
The cost of a diagnosis of an acute exacerbation was
€339, the overall treatment cost was €305 (corticoste-
roids, antibiotics, and anticoagulants and non-invasive
ventilation) and the cost of healthcare resource use and
follow-up during an acute exacerbation was €11,074 per
patient. Therefore, the total cost of an acute exacerba-
tion was €11,718, with healthcare resource use and
follow-up representing 95 % of the total cost. The overall
cost associated with acute exacerbations per year was
€8,882 per patient with stable disease, €9,646 per patient
with slow disease progression and €20,511 per patient
with rapid disease progression (Table 5). Weighting
these costs per type of disease course showed a global
cost of €11,666 per patient per year (Table 5).
The mean total cost of end-of-life care treatment was
€463 per patient, regardless of the type of disease course.
The cost of outpatient visits during end-of-life care was
€864 per patient. Therefore, considering both treatment
and medical visits, the total cost of end-of-life care was
€1,327 per patient. Considering the annual mortality rate
for each type of disease course, the mean associated cost of
end-of-life care per year was €241 for patients with stable
disease, €379 for patients with slow disease progression and
€1,062 for patients with rapid disease progression (Table 5).
The cost weighted by types of disease course showed an
overall cost of €488 per patient per year (Table 5).
Taking into consideration all the factors studied, a
total cost of €11,484, €20,978 and €57,759 were obtained
per year per patient with stable disease, slow disease
progression and rapid disease progression, respectively
(Table 5). Therefore, the cost in patients with rapid dis-
ease progression was about 5 times higher than that for
patients with stable disease and 3 times higher than that
for patients with slow disease progression. Weighting
these costs by the proportion of patients representing
each type of clinical disease course resulted in a mean
cost of €26,435 per patient per year (Table 5; Fig. 1).
Sensitivity analysis
Univariate sensitivity analyses of the prevalence, incidence,
resource use and cost data were made to calculate changes
in total costs when these parameters were varied. The
main parameters that the total cost was most sensitive to
were resource use during the clinical management of ex-
acerbations, treatment and monitoring. The costs associ-
ated with treatment (pharmacological and the cost of
treating adverse events) also changed the results consider-
ably (Table 6).
Discussion
This study aimed to assess treatment patterns, resource
use and associated costs in Spanish patients with IPF.
The results are of interest due to the lack of studies ana-
lysing the burden associated with IPF and may help to
indicate medical needs in the management of patients
with IPF and guide research and investment in health re-
sources. Our study is the first detailed analysis of health-
care costs associated with the overall management of
patients with IPF in Spain, from diagnosis until end-of-
life care.
Our results show that the total annual costs per pa-
tient with stable disease, slow and rapid disease progres-
sion were €11,484, €20,978 and €57,759, respectively.
Weighting these costs by type of disease course showed
a mean cost of €26,435 per IPF patient per year. These
results are comparable to those of a retrospective study
of US claims databases that included 9,286 patients and
Table 5 Total cost per patient per year according to disease course
Stable disease Slow disease progression Rapid disease progression Total cost weighted by type of disease distribution
Diagnosis €1,184.07 €1,184.07 €1,184.07 €1,184.07
Treatment €722.26 €8,069.33 €10,802.52 €7,146.55
Monitoring €453.94 €1,698.91 €24,199.00 €5,949.93
Acute exacerbations €8,882.22 €9,646.21 €20,511.50 €11,666.47
End-of-life care €241.28 €379.15 €1,061.62 €488.07
TOTAL €11,483.76 €20,977.67 €57,758.70 €26,435.10
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found that the total direct cost of IPF was $26,378 per
patient per year [18]. However, there were methodo-
logical differences between this and our study. In the US
study, two cohorts (patients with IPF and matched con-
trols) were retrospectively identified from US claims da-
tabases in order to analyse the prevalence and incidence
of pre-selected comorbidities and to collect data on
healthcare resource use (hospital, outpatient, drugs) in
each cohort; costs were not estimated according to type
of disease course. As reflected by our results, the clinical
course has a considerable impact on disease manage-
ment and costs of treatment. We did not analyse the in-
cidence and prevalence of comorbidities because we
considered that they are not a direct or inevitable conse-
quence of IPF.
In Spain, some studies have evaluated the cost associ-
ated with the management of chronic lung diseases such
as chronic obstructive pulmonary disease (COPD). The
mean annual cost per patient with COPD (including
hospital care, ambulatory care, oxygen therapy, usual
drug therapy and drug therapy for exacerbations) has
been estimated at around €2,000 [19–21], suggesting
that the cost associated with the management of patients
with IPF (€26,435 in our study) is considerably higher
than other chronic lung diseases.
The sensitivity analysis showed that the parameters
with the greatest impact on the results were those
related to healthcare resource use during the clinical
management of exacerbations, treatment and monitor-
ing. The impact of these factors was due to variations in
the estimates of resource use by the clinical experts
(rather than estimated unit costs). This suggests differ-
ences in clinical practice between experts and variations
in access to, or use of, healthcare resources between
health centers. In addition, variations between published
recommendations and clinical practice were found (for
Table 6 Univariate sensitivity analysis
Mean cost per patient per year
Base case €26,435
Parameter Minimum Maximum Minimum. Maximum.
Difference from base case (%) Difference from base case (%)
Prevalence €26,830 €26,198 1 % −1 %
Incidence €26,139 €26,731 −1 % 1 %
Resource use during disease diagnosis €25,349 €27,745 −4 % 5 %
Resource use during treatment by disease course €19,408 €83,145 −27 % 215 %
Resource use during monitoring by disease course €21,882 €51,531 −17 % 95 %
Resource use during clinical management of exacerbations €16,882 €93,113 −36 % 252 %
Resource use during end-of-life care €25,975 €31,351 −2 % 19 %
Cost of medical visits €24,772 €28,574 −6 % 8 %
Cost of hospitalizations €24,926 €28,491 −6 % 8 %
Cost of treatment €24,492 €35,522 −7 % 34 %
Cost of tests €24,127 €28,938 −9 % 9 %
Fig. 1 Costs shown as a percentage of the overall cost by type of disease course
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example, in the use of diagnostic tools such as broncho-
alveolar lavage).
Our results may reflect true variability of the manage-
ment of patients with IPF in Spanish clinical practice,
likely due in part to the lack of effective pharmaco-
logical treatments. It remains to be seen how recently
reported findings in IPF [22–24] and the availability of
new therapeutic options will change treatment patterns
in IPF. Nintedanib was not available at the time that
this Delphi panel was carried out while pirfenidone had
not been reimbursed and was only available through
compassionate use; consideration of these treatments
would probably increase the estimated economic bur-
den associated with IPF.
Lung transplantation is the main determinant of treat-
ment costs in patients with IPF. It might seem that the
number of patients receiving lung transplantation in our
study is low (5 and 8 % of patients with slow and rapid
disease progression, respectively), but considering that 262
lung transplants were performed in Spain in 2014 [25]
and that approximately one third of them are in patients
with IPF [26], it can be extrapolated that approximately
1.3 % of patients with IPF receive a transplantation. It is
also important to note that not all patients with IPF are
candidates for lung transplantation [27].
The incidence and prevalence rates in our study (3
cases per 100,000 people/year and 12 cases per 100,000
people/year, respectively) are within the values in a re-
cent review that estimated an annual incidence of IPF
between 0.22 and 7.4 per 100,000 population and a
prevalence between 1.25 and 23.4 cases per 100,000
population in Europe [28]. The true incidence and
prevalence of IPF are difficult to estimate due to differ-
ences in coding, under- and misdiagnosis, e.g. a recent
Spanish prospective observational study suggested that
almost half of patients diagnosed with IPF may subse-
quently be diagnosed with chronic hypersensitivity pneu-
monitis [29].
One limitation of our study is that it was based on esti-
mates from a Delphi panel and not on prospective or retro-
spective data. The Delphi panel consisted of 15 physicians
who, although selected because of their ILD expertise, may
not be fully representative of Spanish clinical practice.
Nevertheless, it should be taken into account that experts
were chosen from different regions in Spain, and since IPF
is an orphan disease, the number of Spanish experts is lim-
ited. Indirect costs (e.g. work productivity) could not be
determined because experts stated they lacked the informa-
tion required to answer questions related to the impact of
IPF on patients, relatives and caregivers. Studies assessing
indirect costs would help to show the impact of IPF from
the societal perspective. The study results were calculated
on the basis of classifying patients as having stable disease,
slow disease progression or rapid disease progression.
Although these groups correspond to different possible nat-
ural histories of IPF, there is no precise definition of these
terms, which may be a limitation of our study. The Delphi
panel estimates did not distinguish between the outpatient
and inpatient costs associated with exacerbations, treat-
ment, monitoring and end-of-life care. This might have led
to double counting and an overestimate of the costs (the
cost of hospital admissions, for example, already include
the cost of tests, treatments and visits). In contrast, the
calculation of the cost of drug-related adverse events
excluded grade 1–2 adverse effects and grade 3–4 adverse
effects affecting ≤5 % of patients. Therefore, there might
have been an underestimation of the cost of adverse events.
Finally, the number of exacerbations per year could have
been overestimated because the questionnaires of the
Delphi panel did not include a specific definition for an
acute exacerbation of IPF and physicians may have included
worsenings of IPF with an identifiable cause. This could
explain why our results are higher than other data on acute
exacerbations of IPF [30]. Despite these limitations, the
similarities between our results and those of other studies
on the impact of IPF [18] suggest that our study may pro-
vide a reasonable estimate of the cost of IPF in Spain.
Conclusions
The results of this study suggest that the management of
patients with IPF in Spain, and especially patients with
rapid disease progression, has a high economic impact
on the NHS. The cost associated with acute exacerba-
tions represents nearly half of the total cost of managing
patients with IPF and therefore, the availability of new
treatments that reduce the risk of acute exacerbations
may reduce the economic impact of IPF. This study fur-
ther supports the need for treatments modifying the
course of IPF.
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